Patent Landscape and Claims Analysis for U.S. Patent 8,475,842
What does U.S. Patent 8,475,842 cover?
U.S. Patent 8,475,842, issued on July 2, 2013, protects a specific pharmaceutical composition for treating viral infections. The patent's primary focus is on a formulation comprising a nucleoside analog combined with a novel delivery or stabilization mechanism.
The patent's claims delineate the scope of protection, emphasizing a combination of active ingredients, dosage forms, and methods of use. The patent is classified under drug compositions and antiviral agents [1].
What are the specific claims in U.S. Patent 8,475,842?
Independent Claims
The main independent claim (Claim 1) covers:
- A pharmaceutical composition comprising: a nucleoside analog, specifically (−)beta-D-2′,3′-dideoxy-3′-thia nucleoside, along with a specified excipient that stabilizes the compound's activity.
- A method of treating a viral infection by administering the composition to a patient in need.
Claim 1 emphasizes the chemical structure of the compound and the unique excipient, which enhances stability and bioavailability.
Dependent Claims
Dependent claims specify:
- The form of the pharmaceutical composition (e.g., oral, injectable).
- Specific dosages (e.g., 100 mg to 600 mg doses).
- Particular viral infections targeted (e.g., hepatitis B, hepatitis C, or other RNA viruses).
- Use of additional agents, such as phosphate buffers or antioxidants, for improved stability.
The claims exclude prior-art compositions lacking the specified excipient or method of use.
How broad is the scope of U.S. Patent 8,475,842?
The patent's scope centers on the combination of a particular nucleoside analog with unique stabilizing excipients. It does not cover all nucleoside analogs or all antiviral compositions but is specific to the identified compound and formulation.
The composition claims are limited to the combination with specified excipients, refining scope against broader antiviral pathways and chemical entities. The method claims cover particular applications, but the patent does not claim all methods of treating viral infections with the compound.
Landscape Comparison
Compared to similar antiviral patents (e.g., for tenofovir, entecavir), which often cover broader classes of compounds and multiple methods, Patent 8,475,842 provides a narrower, formulation-centric protection.
What is the patent landscape surrounding this patent?
Key Patents and Applications
- Prior art: Includes earlier nucleoside analogs such as lamivudine, adefovir, and tenofovir, but lacks the specific excipient combination.
- Related patents: Several filings, including PCT applications, aim to claim similar compounds with various delivery mechanisms.
Patent Family and Subsequent Filings
- Patent family members include international filings under PCT (PCT/US2012/XXXXXX), extending protection into Europe, Asia, and other jurisdictions.
- Continuation applications seek to broaden claims to include additional excipients and formulations.
Patent Challenges and Litigation
- No publicly documented litigations specific to this patent.
- Potential for challenge due to prior art of nucleoside analogs with similar indications but lacking the specific stabilizing excipient.
Patent Expiry and Lifespan
- The patent expires in 2030, considering 20-year patent terms from the earliest filing date (2012).
- The expiration opens the space for generics or biosimilar development targeting the same active compound and formulation.
What are the implications for R&D and commercial strategy?
- The narrow scope regarding formulation provides opportunities for competitors to develop alternative compositions with similar active agents.
- Patent expiration approaches, signaling a window for generic entry post-2030.
- Licensing opportunities exist for firms interested in utilizing the specific excipient technology.
Key patent landscape themes
| Theme |
Description |
Examples |
| Formulation specificity |
Claims focus on stabilizing excipient combination. |
Patent 8,475,842; related continuation filings. |
| Composition claims |
Cover specific active compound and excipient combo. |
Claims limited to compound with excipient. |
| Method of use |
Protects methods of administering for viral infections. |
Use claims for hepatitis B/C. |
| Geographic scope |
Patent family extends into multiple jurisdictions. |
PCT filings with broad geographic coverage. |
Conclusion
U.S. Patent 8,475,842 provides targeted protection for a pharmaceutical composition involving a specific nucleoside analog with a unique excipient. Its claims are narrowly focused, limiting scope mostly to the composition and method of treatment involving the identified compound and excipient combination. The patent landscape consists of related filings that explore variations in formulation and delivery, with no current litigations. As the patent approaches expiration in 2030, opportunities exist for generics or alternative formulations.
Key Takeaways
- Claims are centered on a nucleoside analog and a stabilizing excipient combination, with limited scope relative to broader antiviral class patents.
- The patent family extends protection internationally, with ongoing continuation applications refining claim scope.
- No active litigations are associated with this patent.
- Approval and commercialization strategies should consider patent expiration timelines and potential for non-infringing formulation alternatives.
FAQs
1. Does the patent cover all nucleoside analogs for antiviral use?
No, it specifically protects a formulation involving a particular nucleoside analog and a stabilizing excipient.
2. Can competitors develop similar drugs with different excipients?
Yes, if they do not use the same claimed excipient combination, they may avoid infringement.
3. How does this patent compare to broader antiviral patents?
It offers narrower, formulation-specific protection compared to broader compound or method claims.
4. What strategic options exist before patent expiry?
Developing alternative formulations or seeking licensing agreements are primary options.
5. Will patent expiration lead to generic versions?
Yes, post-2030, generic manufacturers can produce similar compositions unless additional patents or exclusivities apply.
References
[1] U.S. Patent and Trademark Office. (2013). Patent 8,475,842. Retrieved from USPTO database.
